Amy P. Jain

Ophthalmology

366 San Miguel Dr
Suite 206
Newport Beach, CA 92660

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.

Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease.

Journal: The Journal of clinical endocrinology and metabolism

Published: February 13, 2023

Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.

Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.

Journal: Ophthalmology

Published: June 13, 2021

Thyroid eye disease: Redefining its management-A review.

Thyroid eye disease: Redefining its management-A review.

Journal: Clinical & experimental ophthalmology

Published: October 05, 2020

Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease.

Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease.

Journal: The British journal of ophthalmology

Published: September 02, 2020

Showing 1-4 of 4

Last Updated: 09/26/2026